ASCO Career Development Award: Application Guide

The ASCO Career Development Award (CDA) is a mentored research grant administered by Conquer Cancer, the ASCO Foundation, designed to establish early-career physician-investigators as independent clinical cancer researchers. Initiated to bridge the transition between fellowship training and sustained academic funding, the award provides multi-year operating support and protected investigative time for clinician-scientists who hold their initial faculty appointment. As described on the official Conquer Cancer portal on November 8, 2026, the award strictly requires patient-oriented clinical or translational investigations conducted under the active supervision of a designated scientific mentor.

Establishing an independent clinical trial portfolio is a cornerstone of professional advancement within academic oncology, where clinician-investigators translate biological insights into therapeutic protocols across oncology subspecialties.

What it is and who runs it

The Career Development Award is operated and funded by Conquer Cancer, the ASCO Foundation—the philanthropic arm of the American Society of Clinical Oncology (ASCO). Established in 1992, the CDA specifically funds clinical investigators in the early stages of their faculty appointments. Since the inception of its broader Grants & Awards programme in 1984, Conquer Cancer has distributed more than $215 million across more than 10,500 grants and awards to support oncology discoveries and clinical care improvements.

The primary mandate of the CDA is to support physicians during the critical window when institutional startup packages must be converted into sustained extramural funding. The CDA is defined as a mentored mechanism: every recipient works alongside a primary scientific mentor who oversees project execution, professional development, and career trajectory at the grantee’s home institution.

The program operates within the broader landscape of early-career support structures, frequently functioning alongside institutional seed funding and philanthropic initiatives detailed in our guide to foundation grants for early-career investigators.

Eligibility

As documented on the official Conquer Cancer grants page on November 8, 2026, applicants must satisfy strict professional, temporal, and clinical criteria to qualify for the Career Development Award:

Professional credentials: Applicants must be physicians holding an MD, DO, or international equivalent medical degree, actively engaged in patient care and patient-oriented research.
Faculty appointment timing: The candidate must hold an initial full-time faculty appointment (typically as an Instructor, Assistant Professor, or international equivalent) at an accredited medical school or research institute. Per official program documentation, applicants must be in the first to fourth year of their initial faculty appointment at award activation.
Mentorship structure: Each applicant must have an established primary scientific mentor at their home institution who provides laboratory facilities, clinical trial infrastructure, and oversight. Co-mentors may provide specialized statistical or translational guidance.
ASCO membership: The candidate must be an active member of ASCO (or have submitted an application concurrently) and have the formal endorsement of their department chair.
Geographic eligibility: The CDA accepts applications from qualified clinical researchers based at both US and international academic institutions.

What it funds or requires

The CDA provides three consecutive years of research funding, structured to cover personnel costs and direct project expenses. Key award requirements include:

Protected research time: The recipient’s institution must formally guarantee dedicated protected time—shielded from routine clinical service and administrative responsibilities—to execute the mentored research plan.
Scope of allowable research: The proposed study must maintain a patient-oriented focus. Allowable proposals include clinical trials, patient-reported outcome interventions, biomarker analyses from clinical trials, and translational studies involving direct human specimens.
Disqualified project types: Conquer Cancer explicitly disqualifies projects focused predominantly on in vitro experiments, cell culture assays, or animal model systems, even if those models have clinical relevance. Projects must center on human subjects or clinical materials.
Direct cost allowances: Award funds support investigator salary, fringe benefits, specialized supplies, patient accrual costs, biostatistical consultation, and travel to the annual ASCO meeting. Indirect institutional overhead costs are restricted according to foundation policy.

Investigators managing clinical trials under this mechanism frequently navigate specialized subspecialty workflows, such as those evaluated in our comparison of oncology vs hematology practice.

Application or compliance steps

Applying for the ASCO Career Development Award involves a structured preparation process administered through ASCO’s application portal:

Identify mentor and advisory team: Select an established primary mentor with an active track record of extramural grant funding and mentorship success in clinical oncology.
Confirm institutional eligibility: Obtain written verification from the department chair confirming faculty status, institutional resources, and guaranteed protected time.
Draft the research proposal: Develop a research strategy outlining specific aims, background, preliminary data, clinical research design, statistical power calculations, and potential pitfalls with direct patient involvement.
Formulate the career development plan: Write a comprehensive training statement describing coursework, clinical trial management training, regulatory governance, and planned transitions to independent national grant mechanisms.
Submit letters of support: Upload structured letters from the primary mentor, collaborators, and institutional officials detailing mentorship commitments.
Manage post-award compliance: If funded, submit annual scientific progress reports, financial accounting statements, and updates regarding clinical trial approvals (IRB protocols).

Typical timeline phases

While calendar dates vary annually across funding cycles, the ASCO CDA follows a consistent seasonal progression:

Phase 1: Announcement and RFP release (Summer): Conquer Cancer issues the annual Request for Proposals (RFP), outlining funding tracks and application guidelines.
Phase 2: Proposal submission (Early Autumn): Full applications, mentor commitments, and institutional authorization letters are submitted through the online grants portal.
Phase 3: Scientific peer review (Autumn to Winter): A multidisciplinary study section reviews applications, scoring proposals on candidate potential, research merit, mentorship quality, and institutional environment.
Phase 4: Funding notification (Spring): Applicants receive formal funding decisions, negotiate award terms, and finalize regulatory approvals.
Phase 5: Award activation (Summer): Grants activate on July 1, coinciding with formal recognition during the ASCO Annual Meeting.

Common mistakes

Peer review panels and grant administrators identify several recurring shortcomings that weaken CDA submissions:

Over-reliance on laboratory or animal models: Proposals that concentrate primarily on cell culture or animal models are disqualified, as the program strictly requires patient-oriented investigations.
Weak career development plans: Treating the career development section as secondary. Reviewers evaluate structured training in biostatistics, clinical trial design, and leadership.
Insufficient mentor engagement: Submitting a generic mentor letter that lacks a concrete plan for regular meetings, co-authorship milestones, or grant transition strategies.
Unclear intellectual property separation: Failing to articulate how the proposed project differentiates the junior investigator from their mentor’s existing funded portfolio.
Ambiguous protected time guarantees: Providing vague statements regarding clinical effort rather than a binding departmental letter guaranteeing dedicated research time.

Related programs

Conquer Cancer and federal funding agencies offer a sequence of career development mechanisms tailored to distinct professional stages in oncology research:

Grant Mechanism	Funding Organization	Target Career Stage	Typical Duration & Scope
ASCO Career Development Award (CDA)	Conquer Cancer (ASCO)	Junior faculty (years 1–4 of appointment)	3 years; mentored patient-oriented clinical cancer research
ASCO Young Investigator Award (YIA)	Conquer Cancer (ASCO)	Fellows in final training years transitioning to faculty	1 year; preliminary clinical oncology research and pilot data generation
Global Oncology Young Investigator Award	Conquer Cancer (ASCO)	Early-career investigators in global oncology	1 year; clinical research addressing low- and middle-income country cancer burdens
NCI Mentored Clinical Scientist Award (K08)	National Cancer Institute (NIH)	Junior clinician-investigators with clinical doctorate	3–5 years; mentored laboratory, translational, or patient-oriented oncology research
NCI Patient-Oriented Research Award (K23)	National Cancer Institute (NIH)	Junior clinical researchers focusing on human subjects	3–5 years; intensive mentored research directly with patient cohorts

Recipients of early-career foundation grants routinely leverage preliminary findings to compete for federal funding mechanisms, including R01 research grants detailed in our NCI funding guide and institutional cancer research funding overview. Understanding how environmental carcinogens are identified further informs clinical trial design, as documented in our IARC list of carcinogens guide.

FAQ

What is the difference between the ASCO CDA and the ASCO Young Investigator Award (YIA)?

The primary difference is career timing and funding duration. The Young Investigator Award (YIA) is designed for subspecialty fellows during their final years of training as they transition into faculty roles, providing one year of seed funding. The Career Development Award (CDA) is designed for investigators who already hold their initial faculty appointment (within years 1 through 4), providing three years of support to build an independent clinical research portfolio.

Can international oncologists apply for the ASCO Career Development Award?

Yes. Conquer Cancer accepts CDA applications from physician-investigators at accredited academic and medical institutions globally. Applicants must be active ASCO members, have a qualified institutional mentor, and fulfill the faculty appointment and patient-oriented research criteria.

Are animal-only research projects eligible for the ASCO CDA?

No. Conquer Cancer guidelines strictly require that the research project maintain a patient-oriented focus, which includes clinical trials or translational investigations utilizing human subjects or human-derived specimens. Proposals with a predominant focus on in vitro or animal models are ineligible for CDA funding.

How does the ASCO CDA interface with federal NIH K awards?

The ASCO CDA is often viewed as a vital stepping stone toward federal mentored career awards (such as NIH K08 or K23 grants) or as a major parallel achievement. Junior faculty who receive a CDA demonstrate extramural peer-reviewed competitiveness, pilot feasibility, and institutional backing, significantly strengthening subsequent NIH grant applications.

Sources

Conquer Cancer, the ASCO Foundation. Grants & Awards: Career Development Award (CDA) and Young Investigator Award (YIA) Program Guidelines. Published online; accessed November 8, 2026. Available at: https://www.conquer.org/cancer-research/grants-awards.
Conquer Cancer, the ASCO Foundation. 2026 Grants & Awards Program Book: Supporting Physician-Scientists in Clinical Cancer Research. Alexandria, VA; published September 2026. Available at: https://cdn.bfldr.com/KOIHB2Q3/at/tn6whk2725j5394v9v5mvp/2026_G-A_Program_Book_91826-1.pdf.
National Cancer Institute (NCI / NIH). Mentored Clinical Scientist Research Career Development Award (K08) Program Overview. Bethesda, MD; updated 2026. Available at: https://www.cancer.gov/grants-training/training/funding/k08.